JAK1 and rosacea: To evaluate the therapeutic potential of targeting JAK2 signaling in rosacea, LL37-induced mice were treated with ruxolitinib (a JAK1/2 inhibitor) via intragastric administration (IG) or external application (EXT) (Figure 3A).